BeyondSpring Appoints Min Qiu as CEO to Drive DUBLIN-4 Confirmatory Phase 3 Execution

With a confirmatory Phase 3 trial as its near-term inflection point, BeyondSpring has restructured its executive team to concentrate operational accountability on DUBLIN-4, its pivotal program for Plinabulin in post-ICI, EGFR wild-type non-small cell lung cancer. All appointments take effect July 1, 2026.

Min Qiu assumes the CEO role with an explicit mandate covering three areas: completing DUBLIN-4 enrollment and execution, extending Plinabulin's scientific optionality, and broadening the company's global partner and investor base. Na Li joins as Chief Financial Officer to support capital markets engagement across Asian and international counterparties. Dr. Jiangwen (Jen) Majeti, PhD, MBA, moves from Director to Vice Chairman, deepening board-level governance continuity. Dr. Lan Huang transitions to Chairman while committing primary time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and CEO, a deliberate structural separation intended to give each organization a fully dedicated executive leader.

The reorganization is framed around three conditions the board identified as defining BeyondSpring's current position: a differentiated scientific thesis, a confirmatory trial pathway, and an IP portfolio extending well into the next decade. U.S. composition-of-matter protection for Plinabulin currently runs through 2036; upon FDA approval, BeyondSpring intends to pursue a Hatch-Waxman patent term extension that could restore up to five additional years, potentially extending exclusivity to 2041.

The scientific rationale underpinning DUBLIN-4 rests on published Phase 3 data. In the DUBLIN-3 study, reported in The Lancet Respiratory Medicine (2024), Plinabulin combined with docetaxel doubled two- and three-year survival rates in second- and third-line EGFR wild-type NSCLC patients while reducing docetaxel-induced grade 4 neutropenia from 33% to 5%. That tolerability profile carries direct relevance for clinical operations teams managing dose-reduction protocols and treatment-interruption rates.

New preclinical data presented at the 2026 AACR Annual Meeting extend the asset's profile into the ADC setting. Combinations with T-DXd and Dato-DXd produced higher complete tumor regression rates and improved survival in preclinical models, with or without immunotherapy. The proposed mechanism centers on GEF-H1 activation maturing dendritic cells, elevating the CD8+ T cell-to-Treg ratio, and mitigating neutropenia that drives ADC dose reductions, addressing two persistent barriers to ADC efficacy simultaneously. These findings position Plinabulin as a potential combination partner in a rapidly expanding ADC pipeline, broadening the commercial and development optionality the incoming leadership team will need to prosecute.

Execution against DUBLIN-4's confirmatory endpoints, and the regulatory package that follows, will serve as the primary measure of whether this restructuring delivers the focused accountability the board has signaled as its intent.

Source: BeyondSpring Inc. via GlobeNewswire, June 4, 2026.